VEGF (Vascular endothelial growth factor)

Contents: Carrier-Free Recombinant Human VEGF (Vascular endothelial growth factor)
Catalog Number: 34-8359
Formulation: Sterile liquid; 35% (v/v) acetonitrile, 0.1% (v/v) trifluoracetic acid with no carriers or stabilizers. 0.22 uM filtered.
Storage Conditions: For greatest stability, keep concentration of primary stock at or above 10 µg/ml. For long term storage, aliquot into polypropylene vials (volumes of 20 µl or greater) and store at or below -80°C. Avoid repeated freeze/thaw cycles.
Handling Conditions: For best recovery, always quick-spin vial prior to opening. For dilution of current stock, always include carrier protein (1% BSA or 10% FBS) in the buffered saline diluent.
Source: E. coli expressed amino acids ala 27-arg 147 of mature human VEGF121 (accession # AF214570).
Molecular Mass: The protein is not methionylated at the N-terminal and has a predicted molecular mass of 14,071. The DTT reduced protein migrates as a 14 kDa doublet on SDS-PAGE. The cystine-linked homodimer migrates as a 29 kDa protein on non-reduced SDS-PAGE.
Purity: Greater than 98% as determined by SDS-PAGE
Endotoxin Level: Less than 0.01 ng/ug cytokine as determined by the LAL assay.
Bioactivity: Measured by human umbilical vein endothelial cell proliferation assay. The ED₅₀ is typically 10.0 ng/ml, corresponding to a specific activity of 1.0 x 10⁵ Units/mg.

Prices for This Product*
Cat. No.	Size	Price	Qty	Action
34-8359-82	100 ug	$1800
34-8359-85	500 ug	$2000

*International customers: Please contact your distributor for region specific pricing.

Available Formats of This Product
Cat. No.	Format	Excite (nm)	Emit (nm)	Reported Applications
34-8359	Carrier-Free Recombinant Human VEGF (Vascular endothelial growth factor)	N/A	N/A	BA
14-8359	Recombinant Human VEGF (Vascular endothelial growth factor)	N/A	N/A	BA

Questions? Please consult our answers to frequently asked questions at http://www.ebioscience.com/faq.

Description

Vascular endothelial growth factor (VEGF), also called vascular permeability factor (VPF), is produced by cultured vascular smooth muscle cells. From analysis of transcripts from these cells by PCR and cDNA cloning, 3 different forms of the VEGF coding region have been identified. These cDNAs had predicted products of 189, 165, and 121 amino acids. VEGF is a mitogen primarily for vascular endothelial cells. It is structurally related to platelet-derived growth factor. VEGF, a homodimeric glycoprotein of relative molecular mass 45,000, is the only mitogen that specifically acts on endothelial cells. The VEGF receptor, Flk1, is exclusively expressed in endothelial cells. VEGF may be a major regulator of tumor angiogenesis in vivo.

Applications Reported

For research use only, not for diagnostic or therapeutic use. The recombinant human VEGF has been reported for use in bioassays.

Applications Tested

This recombinant human VEGF has been tested by bioassay of human umbilical vein endothelial cells (HUVEC). Dose-dependent induction of proliferation of HUVECs yields an ED₅₀ of 10.0 ng/ml, corresponding to a specific activity of approximately 1x10⁵ Units/mg.

References

Tischer, E., et al. 1991. The human gene for vascular endothelial growth factor: multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266: 11947-11954.
Millauer, B., et al. 1994. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576-579. Folkman, J. 1995. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1: 27-31.